| Author | Guterres, Alexandro | |
| Author | Abrahim, Mayla | |
| Author | Neves, Patrícia Cristina da Costa | |
| Access date | 2024-08-16T17:42:59Z | |
| Available date | 2024-08-16T17:42:59Z | |
| Document date | 2023 | |
| Citation | GUTERRES, Alexandro; ABRAHIM, Mayla; NEVES, Patrícia Cristina da Costa. The role of immune subtyping in glioma mRNA vaccine development. Immunotherapy, v. 15, n. 13, p. 1057-1072, Sept. 2023. | en_US |
| ISSN | 1750-743X | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/65405 | |
| Sponsorship | Financial & competing interests disclosure: The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. | |
| Language | eng | en_US |
| Publisher | Taylor & Francis | en_US |
| Rights | restricted access | |
| Title | The role of immune subtyping in glioma mRNA vaccine development | en_US |
| Type | Article | |
| DOI | 10.2217/imt-2023-0027 | |
| Abstract | Studies on the development of mRNA vaccines for central nervous system tumors have used gene expression profiles, clinical data and RNA sequencing from sources such as The Cancer Genome Atlas and Chinese Glioma Genome Atlas to identify effective antigens. These studies revealed several immune subtypes of glioma, each one linked to unique prognoses and genetic/immune-modulatory changes. Potential antigens include ARPC1B, BRCA2, COL6A1, ITGB3, IDH1, LILRB2, TP53 and KDR, among others. Patients with immune-active and immune-suppressive phenotypes were found to respond better to mRNA vaccines. While these findings indicate the potential of mRNA vaccines in cancer therapy, further research is required to optimize administration and adjuvant selection, and precisely identify target antigens. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Vice Diretoria de Desenvolvimento Tecnológico. Laboratório de Tecnologia Imunológica. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Vice Diretoria de Desenvolvimento Tecnológico. Laboratório de Tecnologia Imunológica. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Vice Diretoria de Desenvolvimento Tecnológico. Laboratório de Tecnologia Imunológica. Rio de Janeiro, RJ, Brasil. | en_US |
| Subject | Brain tumor | en_US |
| Subject | Central nervous system | en_US |
| Subject | Immunotherapeutic | en_US |
| Subject | mRNA-based drugs | en_US |
| Subject | mRNA vaccines | en_US |
| Subject | Tumors | en_US |
| e-ISSN | 1750-7448 | |
| Embargo date | 2030-12-31 | |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
